Hansa Biopharma participating in Pareto Securities’ 17th Annual Healthcare Conference 2026

Lund, Sweden, 27 August. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be presenting at Pareto Securities’ 17th Annual Healthcare Conference 2026 in Stockholm, at 12:45-13:05 CEST, on Wednesday 2 September, as well as participating in a panel discussion later that day at 14:50-15:10 CEST.

If you are interested in meeting with Hansa’s management, please contact Hansa Biopharma at ir@hansabiopharma.com.

Event: Pareto Securities’ 17th Annual Healthcare Conference 2026

Date and Place: Wednesday 2 September, Stockholm

Speaker: Renée Aguiar-Lucander, CEO, Hansa Biopharma

Corporate Presentation: 12:45-13:05 CEST

Panel Discussion: 14:50-15:10 CEST

--- ENDS ---

Contacts for more information:

Adam Cutler, Chief Financial Officer
IR@hansabiopharma.com

Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa’s proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company’s portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.